Sakurai Y, Takahashi R, Nakahara T, Ikenaga H
Arch Gen Psychiatry. 1980 Sep;37(9):1057-62. doi: 10.1001/archpsyc.1980.01780220095011.
A blink controlled study evaluated the prediction of response to chlorpromazine treatment in 37 schizophrenics on the basis of actual outcomes. Prior to the initiation of treatment, blood samples were taken three hours after a dose of 50 mg of chlorpromazine for the analyses of the drug and its metabolites. The chlorpromazine therapy was then begun and continued for three months. The results agreed with our previous conclusion that patients who showed high levels of the metabolites after a single dose of chlorpromazine tended to have poor clinical improvement with chlorpromazine and that the responders showed the opposite pattern. The predictability of response to chlorpromazine therapy is significantly high in the patients with very low or high levels of the metabolites. However, this is useful at best in 46% of the subjects studied.
一项采用眨眼控制的研究，基于实际结果评估了37名精神分裂症患者对氯丙嗪治疗反应的预测情况。在开始治疗前，给予50毫克氯丙嗪一剂，三小时后采集血样以分析药物及其代谢产物。然后开始氯丙嗪治疗并持续三个月。结果与我们之前的结论一致，即单剂量氯丙嗪后代谢产物水平高的患者，使用氯丙嗪治疗后的临床改善往往较差，而有反应者则呈现相反模式。对于代谢产物水平极低或极高的患者，对氯丙嗪治疗反应的可预测性显著较高。然而，在研究的受试者中，这充其量对46%的人有用。
